CHEMELLO, LILIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.089
AS - Asia 11.408
EU - Europa 5.203
SA - Sud America 2.268
AF - Africa 2.232
OC - Oceania 221
Continente sconosciuto - Info sul continente non disponibili 109
Totale 38.530
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.967
SG - Singapore 3.646
CN - Cina 1.870
VN - Vietnam 1.575
BR - Brasile 1.367
HK - Hong Kong 1.218
FI - Finlandia 642
IT - Italia 558
DE - Germania 554
FR - Francia 483
PL - Polonia 425
IN - India 314
SE - Svezia 262
BD - Bangladesh 227
IQ - Iraq 206
RU - Federazione Russa 203
TR - Turchia 192
UA - Ucraina 189
AR - Argentina 188
GB - Regno Unito 164
PK - Pakistan 153
SA - Arabia Saudita 139
ZA - Sudafrica 128
ID - Indonesia 122
EC - Ecuador 119
PH - Filippine 118
CO - Colombia 110
MX - Messico 110
NL - Olanda 108
JP - Giappone 106
IE - Irlanda 95
MA - Marocco 90
AT - Austria 89
NP - Nepal 88
UZ - Uzbekistan 86
ES - Italia 85
ET - Etiopia 85
PE - Perù 84
VE - Venezuela 84
EG - Egitto 81
CI - Costa d'Avorio 76
JO - Giordania 76
LB - Libano 75
PY - Paraguay 74
MN - Mongolia 73
AE - Emirati Arabi Uniti 72
CA - Canada 72
PS - Palestinian Territory 72
KR - Corea 70
LC - Santa Lucia 70
SI - Slovenia 70
CL - Cile 69
JM - Giamaica 69
TN - Tunisia 68
DZ - Algeria 67
KG - Kirghizistan 67
MK - Macedonia 67
NO - Norvegia 67
AL - Albania 66
CZ - Repubblica Ceca 65
MY - Malesia 64
RO - Romania 64
ZM - Zambia 64
TH - Thailandia 63
TT - Trinidad e Tobago 63
AO - Angola 62
UY - Uruguay 62
KE - Kenya 61
AZ - Azerbaigian 60
BZ - Belize 60
KZ - Kazakistan 60
PA - Panama 60
GT - Guatemala 58
AU - Australia 57
GR - Grecia 57
PR - Porto Rico 57
ZW - Zimbabwe 57
BG - Bulgaria 56
CV - Capo Verde 56
CW - ???statistics.table.value.countryCode.CW??? 56
MZ - Mozambico 56
BO - Bolivia 55
CR - Costa Rica 55
PT - Portogallo 55
RS - Serbia 55
BF - Burkina Faso 54
CG - Congo 54
DO - Repubblica Dominicana 54
NG - Nigeria 54
BE - Belgio 53
GA - Gabon 53
IS - Islanda 53
BY - Bielorussia 52
GN - Guinea 52
HN - Honduras 52
NI - Nicaragua 52
GF - Guiana Francese 51
GM - Gambi 51
HR - Croazia 51
IL - Israele 51
Totale 35.995
Salva come PNG Salva come JPEG
Città #
Singapore 2.117
San Jose 1.877
Fairfield 1.641
Ashburn 1.536
Jacksonville 1.239
Hong Kong 1.110
Woodbridge 945
Houston 874
Chandler 816
Wilmington 772
Cambridge 600
Seattle 543
Ann Arbor 472
Ho Chi Minh City 469
Princeton 410
Boardman 390
Hanoi 370
Bytom 351
Helsinki 285
Lauterbourg 279
Santa Clara 235
Medford 231
Beijing 228
Los Angeles 216
San Diego 207
Nanjing 191
New York 136
Munich 121
Roxbury 118
São Paulo 117
Guangzhou 111
Buffalo 87
Dublin 86
Baghdad 82
Des Moines 77
Chicago 76
Tashkent 75
Amman 72
Haiphong 71
Ulan Bator 71
Addis Ababa 69
Abidjan 68
Castries 68
Da Nang 68
Shenyang 67
Dong Ket 64
Nanchang 61
Bishkek 60
Hebei 60
Lusaka 60
Milan 60
Hefei 58
Baku 57
Lima 56
Changsha 54
Jiaxing 54
Panama City 54
Vienna 54
Harare 53
Libreville 53
Luanda 53
Montevideo 53
Padova 52
Conakry 50
Redondo Beach 50
Tianjin 50
Bamako 49
Dallas 49
Jeddah 49
Kampala 49
Managua 49
Nairobi 49
Tokyo 48
Bridgetown 47
Riyadh 47
Willemstad 47
Dakar 46
Lahore 46
Maputo 45
Orem 45
Norwalk 44
Rome 44
Dushanbe 43
Guayaquil 43
Nuremberg 43
Antananarivo 42
Cotonou 42
Minsk 42
Rio de Janeiro 42
Reykjavik 41
Vientiane 41
Accra 40
Istanbul 40
Ouagadougou 40
Praia 40
Riga 40
Tirana 40
Turku 40
Nassau 39
Phnom Penh 39
Totale 22.700
Salva come PNG Salva come JPEG
Nome #
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 297
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort 285
In-Hospital Screening Campaign Against Hepatitis C Could Be Effective for Identifying More Patients Who Still Need Treatment 257
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 248
Liver Fibrosis and Steatosis in Alstrom Syndrome: A Genetic Model for Metabolic Syndrome 248
Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. 247
Prognostic value of liver and spleen stiffness in patients with fontan associated liver disease (Fald): A case series with histopathologic comparison 242
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 236
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 236
Surgical management of failing Fontan circulation: Results from 30 cases with 285 patient-years follow-up 235
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. 233
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 223
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 221
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 219
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 216
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 215
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 215
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 214
Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. 214
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 214
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 211
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 209
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma 207
ANTIBODY TO THE POLYALBUMIN (pHSA) RECEPTOR ON HEPATITIS B VIRUS IN ACUTE INFECTION AND IN VACCINE RECIPIENTS 203
Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction 202
Profiles of HCV core protein and viremia in chronic hepatitis C: Possible protective role of core antigen in liver damage 199
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS 198
Liver stellate cells in chronic viral hepatitis : the effect of interferon therapy. 198
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C 197
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 197
Kinetic of virological response during PEG-IFNs in chronic hepatitis C. 191
Serum hepatitis B virus DNA in acute hepatitis type B 191
HEPATITIS C VIRUS SEROTYPES AND LIVER PATHOLOGY 189
Acute hepatitis C virus infection in a nurse trainee following a needlestick injury 189
Chronic evolution of acute hepatitis type B: prevalence and predictive markers 188
A model to predict long-term sustained response to interferon therapy in chronic hepatitis C 187
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 187
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 185
METABOLIC SYNDROME INDUCES A MORE RAPID PROGRESSION OF FIBROSIS IN PRIMARY BILIARY CIRRHOSIS IN EARLY STAGE 185
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 184
Heart rate variability parallels changes in psychiatric scales in interferon-treated patients with chronic hepatitis. 183
HEPATITIS C VIRUS RNA PROFILES IN CHRONICALLY INFECTED INDIVIDUALS: DO THEY RELATE TO DISEASE ACTIVITY? 183
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 181
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 179
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 179
THE EFFECT OF INTERFERON ALFA AND RIBAVIRIN COMBINATION THERAPY IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C 177
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels 177
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C 175
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. 175
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 175
Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals 172
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 171
Antibody response to pre-S2 and hepatitis B virus induced liver damage. 171
HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND HEPATITIS-C PATHOLOGY 170
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 169
Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. 169
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 168
Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. 167
Alterazioni neurovascolari nell’epatite cronica C: uno studio caso-controllo 166
OUTCOME OF ACUTE HEPATITIS C AND ROLE OF ALPHA INTERFERON THERAPY 166
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 166
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals 166
Natural history of hepatitis C. 165
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 162
COMPARISON OF THRICE WEEKLY VS DAILY HUMAN LEUCOCYTE INTERFERON-ALPHA THERAPY FOR CHRONIC HEPATITIS C. TVVH STUDY GROUP. 162
Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population 162
Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Analysis by polymerase chain reaction. 162
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. 161
Therapy of hepatitis C: re-treatment with alpha interferon. 161
The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence 160
KINETIC OF VIROLOGICAL RESPONSE DURING PEG-IFNS IN CHRONIC HEPATITIS C. 160
A COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS OF VARICEAL BLEEDING STARTING FROM SMALL ESOPHAGEAL VARICES COMPARED TO SURVEILLANCE AND TREATMENT STARTING FROM LARGE ONES 159
Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. 159
SCCA EXPRESSION IN PBMCs IN PATIENTS WITH CHRONIC HEPATITIS C 154
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 154
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 153
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 151
A MODEL TO PREDICT SUSTAINED RESPONSE TO THERAPY AND TO OPTIMIZE THE DOSE OF INTERFERON IN CHRONIC HEPATITIS C 150
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa‐2A interferon 149
ALTERAZIONI DELL'ATTIVITA' NATURAL KILLER IN CORSO DI INFEZIONE DA VIRUS EPATITICI 148
Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. 148
Chonic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. 147
The cognitive effects of long-term interferon treatment for chronic viral hepatitis 147
BIOLOGIA MOLECOLARE APPLICATA AL VIRUS DELL'EPATITE B. STUDIO DEL DNA VIRALE NEL SIERO E NEL FEGATO E CORRELAZIONE CLINICA 147
DEREGOLAZIONE DELL’ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) NEI LINFOCITI B IN PAZIENTI INFETTI DA HCV 146
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 146
NATURAL KILLER ACTIVITY IN PATIENTS WITH ACUTE VIRAL HEPATITIS 145
CLINICAL SIGNIFICANCE OF SERUM AND LIVER TISSUE SCCA IN CHRONIC HEPATITIS 145
RELATIONSHIP BETWEEN HBcAg IN SERUM AND LIVER AND HBV REPLICATION IN PATIENTS WITH HBsAg POSITIVE CHRONIC LIVER DISEASE 145
Preventing interferon-induced depression in a sample of 44 chronic hepatitis C patients with risk factor for depression 144
Validation of a new sonographic parameter (liver/kidney ratio of greys intensity of digital images) for diagnosis and quantification of liver steatosis 144
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 143
Natural killer activity in patients with acute viral hepatitis 143
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 143
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS. 142
[Study of the hepatitis B virus-neutralizing response in acute infection and in patients vaccinated against the infection]. 141
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 140
Anti-interferon antibodies during interferon therapy for chronic hepatitis C. 140
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay. 140
Changes in serum tryptophan during antiviral therapy with recombinant alfa-interferon in chronic hepatitis C 139
Totale 18.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.055
article - articoli 80.154
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 874
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.352
Totale 190.435
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021400 0 0 0 0 0 0 0 0 0 0 174 226
2021/20222.678 42 481 200 241 78 150 112 262 139 52 305 616
2022/20231.972 600 160 62 145 315 233 8 115 194 23 100 17
2023/2024817 38 102 81 51 36 74 48 29 21 22 124 191
2024/20255.219 4 308 197 135 715 76 182 321 555 231 1.030 1.465
2025/202620.000 642 1.931 3.488 3.358 1.587 746 2.365 1.870 2.157 1.226 630 0
Totale 38.606